Breast Cancer Clinical Trial
The purpose of this study is to evalute whether CAD (computer-aided detection) in FFDM (full-field digital mammography) can facilitate the detection rate of breast cancer on mammography compared with FFDM without CAD.
Mammography is currently the only documented effective imaging tool for breast cancer
screening. However, the sensitivity of mammography may be reduced in dense breasts, and
sometimes it is difficult to even perceive a very subtle cancer which presents as a small
stellate lesion, or very faint microcalcifications, missed diagnosed thus occurs. Herein,
some researchers in Western countries developed computer-aided detection (CAD) system to
help radiologists detect subtle, easily overlooked findings to facilitate early breast
cancer detection, and most of the research regarding CAD was used in screen-film mammography
(SFM) system. Ikeda, et al, worked on the retrospective CAD usage of those negative
mammograms which later developed breast cancers. CAD could correctly mark 40% of the areas
on these mammograms reported negative previously that later developed evident cancers.
However, 80% of these are only nonspecific findings, and do not warrant recall for
additional workup even at retrospective unblinded review by well-trained mammographers. The
other research concluded that CAD could improve early cancer detection rate of mammography,
with the sensitivity of 92% in detection of breast cancer size smaller than 5mm, 94% for
cancer size 11-15mm. CAD can detect more microcalcifications than masses (sensitivity for
microcalcifications 98%, masses 84%, mass with microcalcifications 92%). CAD could mark an
average of 1.3 false positive marks per mammographic exam.
Full-field digital mammography (FFDM) is a new approved technology for breast cancer
detection after SFM era since 2000. The diagnostic accuracy of FFDM versus SFM is still
under clinical trials, and it is believed the sensitivity and accuracy of FFDM for screening
population is relatively equivalent to SFM. However, there are very few reports regarding
the CAD application in FFDM, since FFDM can offer the post-acquisition processing on
high-resolution review workstation for interpretation. Nevertheless, the spatial resolution
of soft-copy reading on monitors for FFDM is slightly inferior to but the contrast
resolution is slightly superior to that of conventional SFM. Herein, the diagnostic efficacy
and role of CAD in FFDM are still unclear. Therefore, the goal of our study is to explore
the sensitivity, false-negative (FN) and false-positive (FP) rates of combination usage of
CAD in FFDM system, in comparison with the sensitivity, FN and FP rates of interpretation
based on FFDM without CAD combination. We are also about to evaluate the efficacy,
additional time spent in adjunct application CAD in FFDM interpretation, in order to assess
the feasibility of CAD in FFDM.
;
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |